MUC16 and ovarian cancer: With CA-125 currently integrated into international guidelines for workup of adnexal masses, this difference in false-negative CA-125 rates by race may lead to underworkup and underreferral of American Indian and Black patients, contributing to a later-stage diagnosis of ovarian cancer in these patients.